Risk factor
Very high price volatility
Profitability factor
Very favourable analyst view
About
Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of PGEN is 8.2 and suggests 75% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell